Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective? https://t.co/W8dHEA1tNu

Taking stock:  European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations   https://t.co/Ar1IA9H3ss

Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme https://t.co/zn3nhxrvHU

Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry? https://t.co/6WoHxLdRVR

Thanks for a great Day 1. The GPI team looks forward to doing it all again today! #PPMA @globalpricing

The GPI team looks forward to meeting all delegates at PPMA in London next week (# Stand 31). We are running a short GPI PPMA Challenge Quiz for congress delegates. Go on to the PPMA EU 2018 Congress App for details. #PPMA

What will shape the global pharmaceutical pricing environment in 2018? https://t.co/9vyE96EBgI

Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER

FDA approves pill with sensor that digitally tracks if patients have ingested their medication #innovation #adherence

Humira becomes Boehringer’s first biosimilar approved in Europe #biosimilars #access #innovation

New research highlights countries using International Referencing Pricing for price setting #pricing #strategy

Looking forward to ISPOR Glasgow? Drop by our poster and say "Hello"
ANALYSIS OF USING IRP AS A LAUNCH PRICE SETTING MECHANISM

‘Breakthrough’ tag for GSK’s multiple myeloma drug #innovation #access

Load More...